AI assistant
ARTRYA LIMITED — Call Transcript 2022
Jul 19, 2022
64483_rns_2022-07-19_dfd147fc-4347-4b76-a035-14d86793b36a.pdf
Call Transcript
Open in viewerOpens in your device viewer
Coronary Artery Disease. We see you.
==> picture [596 x 15] intentionally omitted <==
==> picture [92 x 19] intentionally omitted <==
ASX ANNOUNCEMENT
20 July 2022
QUARTERLY RESULTS CONFERENCE CALL
Artificial intelligence medical technology company Artrya Limited (ASX: AYA, Artrya or the Company) will be releasing its June 2022 quarterly report to the ASX on Tuesday, 26 July 2022.
The Company advises it will be holding an investor and analyst conference call discussing the June 2022 quarter results at 1pm AEST (11am AWST) on Tuesday, 26 July 2022.
Join the conference call on Zoom by clicking here.
This announcement was approved by the Company’s Managing Director, John Barrington, on behalf of the Artrya Board.
For further information please contact
Investor Enquiries: Media Enquiries: John Barrington Felicity Heath Artrya Limited Daymark 0419 850 502 0457 196 603 [email protected] [email protected]
About Artrya
Based in Perth, Western Australia, Artrya was founded in 2018 and commenced operations in early 2019. Artrya Ltd is listed on the Australian Securities Exchange (ASX: AYA).
Artrya is an applied artificial intelligence healthcare company that works alongside clinicians to improve the diagnosis of coronary heart disease and develop a holistic overview of a patient at risk. The Company has developed deep learning algorithms that will allow for the prediction and prevention of acute coronary events.
For more information, see www.artrya.com
Artrya Limited ACN 624 005 741 1257 Hay Street, West Perth WA 6005 PO Box 567, West Perth WA 6872 www.artrya.com T: +61 8 6478 7816